Soluble suppression of tumorigenicity-2 in pregnancy with a small-for-gestational-age fetus and with preeclampsia. (31st December 2023)

• Record Type: Journal Article
• Authors: Kanninen, Tomi; Jung, Eunjung; Gallo, Dahiana M.; Diaz-Primera, Ramiro; Romero, Roberto; Gotsch, Francesca; Suksai, Manaphat; Bosco, Mariachiara; Chaiworapongsa, Tinnakorn
• Is Part Of: Journal of maternal-fetal & neonatal medicine. Volume 36:Number 1(2023)
• Publication Date: 2023-12-31
• Subjects: Fetal growth restriction -- interleukin-33 (IL-33) -- placental disease -- suppression of tumorigenesis-2 -- systemic inflammation -- umbilical artery Doppler -- uterine artery Doppler; Obstetrics -- Periodicals; Perinatology -- Periodicals; Infants (Newborn) -- Diseases -- Periodicals; Neonatology -- Periodicals; 618.2
• DOI: 10.1080/14767058.2022.2153034
• Languages: English
• ISSNs: 1476-7058

Abstract

Abstract: Objective: Preeclampsia and fetal growth disorders are pregnancy-specific conditions that share common pathophysiological mechanisms. Yet, why some patients develop preeclampsia while others experience fetal growth restriction, or a combination of both clinical presentations, is unknown. We propose that the difference in severity of the maternal inflammatory response can contribute to the clinical phenotypes of preeclampsia vs. small for gestational age (SGA). To assess this hypothesis, we measured maternal plasma concentrations of the soluble isoform of suppression of tumorigenicity-2 (sST2), a member of the interleukin-1 receptor family that buffers proinflammatory responses. Previous reports showed that serum sST2 concentrations rise in the presence of intravascular inflammation and Th1-type immune responses and are significantly higher in patients with preeclampsia compared to those with normal pregnancy. The behavior of sST2 in pregnancies complicated by SGA has not been reported. This study was conducted to compare sST2 plasma concentrations in normal pregnancies, in those with preeclampsia, and in those with an SGA fetus. Methods: This retrospective cross-sectional study included women with an SGA fetus ( n = 52), women with preeclampsia ( n = 106), and those with normal pregnancy ( n = 131). Maternal plasma concentrations of sST2 were determined by enzyme-linked immunosorbent assay. Doppler velocimetry of the uterine and umbilical arteries was available in a subset of patients with SGA (42 patients and 43 patients, respectively). Results: (1) Women with an SGA fetus had a significantly higher median plasma concentration of sST2 than normal pregnant women ( p = . 008); (2) women with preeclampsia had a significantly higher median plasma concentration of sST2 than those with normal pregnancy ( p < . 001) and those with an SGA fetus ( p < . 001); (3) patients with SGA and abnormal uterine artery Doppler velocimetry had a higher median plasma concentration of sST2 than controls ( p < . 01) and those with SGA and normal uterine artery Doppler velocimetry ( p = . 02); (4) there was no significant difference in the median plasma sST2 concentration between patients with SGA who had normal uterine artery Doppler velocimetry and controls ( p = . 4); (5) among patients with SGA, those with abnormal and those with normal umbilical artery Doppler velocimetry had higher median plasma sST2 concentrations than controls ( p = . 001 and p = . 02, respectively); and (6) there was no significant difference in the median plasma sST2 concentrations between patients with SGA who did and those who did not have abnormal umbilical artery Doppler velocimetry ( p = . 06). Conclusions: Preeclampsia and disorders of fetal growth are conditions characterized by intravascular inflammation, as reflected by maternal plasma concentrations of sST2. The severity of intravascular inflammation is highest in patients with preeclampsia.